paediatrics Brussels 17

Treatment of Posterior Fossa Ependymoma Subgroups

A

B

1.00

1.00

0.75

0.75

0.50

0.50

0.25 PFS (probability) GTR STR

0.25 OS (probability) GTR STR

P = .004

P = .008

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

GTR STR No. at risk

GTR STR No. at risk

63 57 55 51 43 40 34 28 21 15 12 27 22 17 15 11 11 10 8 8 6 5

64 59 57 52 44 40 34 29 22 16 13 27 23 20 18 13 13 12 8 8 6 5

C

D

1.00

1.00

0.75

0.75

0.50

0.50

0.25 OS (probability)

0.25

PFS (probability)

GTR STR

GTR STR

P = .06

P = .02

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

GTR STR No. at risk

GTR STR No. at risk

24 24 21 17 14 12 9 6 5 4 2 23 18 14 10 8 5 4 3 2 1 1

23 23 21 17 14 12 10 8 6 4 2 23 21 19 16 14 10 7 5 4 2 1

Fig A7. Progression-free survival (PFS) and overall survival (OS) EPN_PFB strati fi ed by extent of resection for (A and B) the combined Global Ependymoma Network of Excellence (GENE), St Jude ’ s, and Collaborative Ependymoma Research Network (CERN) cohorts and (C and D) the Burdenko Cohort. GTR, gross total resection; STR, subtotal resection.

© 2016 by American Society of Clinical Oncology

www.jco.org

from 139.18.224.1 Information downloaded from jco.ascopubs.org and provided by at UNIVERSITAETSKLINIKUM LEIPZIG on June 20, 2016 Copyright © 2016 American S ciety of Clinical Oncology. All rights reserved.